CIBICI   14215
CENTRO DE INVESTIGACION EN BIOQUIMICA CLINICA E INMUNOLOGIA
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
METFORMIN TREATMENT MODULATES MACROPHAGE RESPONSE AGAINST T. CRUZI INFECTION
Autor/es:
ANA, Y.; M CECILIA RODRIGUEZ GALAN; CERBAN, FABIO; BAIGORRÍ, RUTH ELIANA; VIANO, MARIA ESTEFANIA; CINTHIA STEMPIN; BRUGO MARIA BELEN; CRISTINA MOTRAN
Reunión:
Congreso; REUNIÓN DE LA SOCIEDAD ARGENTINA DE INMUNOLOGÍA; 2021
Resumen:
In the acute phase of T. cruzi infection, both innate and adaptive immunity are necessary to control parasite replication. Macrophage (Mf) and T cells orchestrate the inflammatory response that controls parasite burden with Th1 cells and production of pro inflammatory cytokines. However, an exacerbated immune response results in tissue damage, mainly by ROS and RNS release. It has been demonstrated that Metformin (Metf), the most used type 2 diabetes drug, reduces inflammation in models of aging and pollution. In our in vivo model of T. cruzi infection with Balb/c mice, we observed that peritoneal and spleen Mf increase iNOS expression during acute phase. We have previously reported that pretreatment of BMDM with Metf prevents intracellular parasite replication and promotes an inflammatory profile in these cells. To determine the effect of Metf against T. cruzi infection, we infected intraperitoneal Balb/c mice with 500 tripomastigotes (tp) and treated the animals with PBS or 100 mg/kg of Metf daily by gavage. At 18 d.p.i. we obtained blood samples, spleen, inguinal lymph nodes and peritoneal lavage including control mice groups. Parasitaemia were assessed in both groups of infected mice showing less tp/mL in Metf treated mice (p